Answers are grounded in this paper and cite their sources.
This commentary discusses challenges in RNA processing and highlights adaptable platforms for scalable manufacturing.
Despite rapid advances in RNA-based vaccines and therapeutics, downstream processing remains a primary constraint on scalable, cost-effective manufacturing. In this commentary article, three researchers at the University of Sheffield discuss key downstream challenges across mRNA and self-amplifying RNA (saRNA), including purification, pre- and post-lipid-nanoparticle processing, as well as analytical limitations, and highlight adaptable, low-shear, digitally enabled platforms as critical enablers of robust RNA manufacturing at scale.
No takes yet. Share an insight, caveat, or question.
Pohare et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: